Tag: ado-trastuzumab emtansine
World ADC 2023 London – What to Expect
With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...
Following Positive Results of Phase III TULIP Trial: FDA Accepts Byondis’...
The U.S. Food & Drug Administration (FDA) has accepted Byondis' submission of a Biologics License Application (BLA) for trastuzumab duocarmazine (previously known as...
HER2, Trastuzumab and the Development of Novel Antibody-drug Conjugates
In the mid-1970s, scientists discovered that certain genes, when mutated, can cause cancer. Based on this observation they theorized that by targeting these oncogenes,...
Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...
The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...
San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...
HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers
Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed signs of clinical activity of...
Ado-trastuzumab emtansine (Kadcyla®)
International Nonproprietary Names (INN)
Ado-trastuzumab emtansine Prescription Drug
Yes Class
Antineoplastic Agents US Brand Name
Kadcyla® Other names
ado-trastuzumab emtansine, trastuzumab-DM1, T-DM1 Available as a generic drug
No Marketing Authorization
Genentech/Roche United States Adopted Name (USAN)
Trastuzumab...
SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in...
Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in the US only) were presented...
Pharmacokinetic Considerations to Maximize an ADC’s Therapeutic Index
The Antibody-drug Conjugate (ADC) field is poised for several significant advances in solid tumors as the industry has built upon knowledge gained over the...
Highlights in Development: September 2019
In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals. Here is an overview of some of...
